摘要
目的探讨丹参酮胶囊对咪喹莫特诱导的银屑病模型小鼠的抗炎和抗氧化应激作用,寻找银屑病的治疗方法。方法使用咪喹莫特乳膏构建银屑病样小鼠模型,通过PASI评分和组织病理评估丹参酮胶囊对银屑病样小鼠模型皮损炎性反应的影响;通过酶联免疫吸附实验检测小鼠血清中白细胞介素(IL)-17A和肿瘤坏死因子(TNF)-α的水平;通过免疫组化和实时荧光定量PCR检测小鼠皮损组织中核因子E2相关因子-2(Nrf2)、抗氧化基因[血红素加氧酶1(HO-1)和超氧化物歧化酶2(SOD2)]和二相解毒酶基因[NAD(P)H醌氧还原酶-1(NQO1)]的表达水平。统计学方法采用单因素方差分析。结果丹参酮胶囊能明显改善银屑病样小鼠炎性反应程度,包括减轻皮肤红斑、鳞屑和皮损厚度。丹参酮胶囊能降低银屑病样小鼠血清中IL-17A和TNF-α水平(均P<0.05)。丹参酮胶囊还能诱导银屑病样小鼠皮肤组织中Nrf2、HO-1和SOD2水平升高(均P<0.05)。结论丹参酮胶囊通过降低银屑病样小鼠血清中IL-17A和TNF-α水平以及激活Nrf2信号通路,从而发挥抗炎和抗氧化应激作用。
Objective To investigate the anti-inflammatory and antioxidant effects of tanshinone capsule on imiquimod-induced psoriatic mouse model,so as to find a treatment for psoriasis.Methods The psoriatic mouse model was constructed with imiquimod cream.The effect of tanshinone capsule on the inflammatory response of psoriatic mouse model induced by imiquimod was evaluated by the PASI score and histopathology,the serum levels of interleukin(IL)-17A and tumor necrosis factor(TNF)-α were determined by enzyme-linked immunosorbent assay,and the expression levels of nuclear factor-E2-related factor 2(Nrf2),antioxidant genes[heme oxygense-1(HO-1)and superoxide dismutase 2(SOD2)],and two-phase detoxification enzyme gene[NAD(P)H quinoneoxid oreductase 1(NQO1)]were detected by the immunohistochemistry and real-time quantitative PCR.The statistical analysis method was one-way ANOVA.Results Tanshinone capsule improved the morphological features of imiquimod-induced psoriasis mice,including reduction of erythema,scales,and skin lesion thickness,thereby reducing the degree of inflammatory response.Tanshinone capsule could reduce the levels of IL-17A and TNF-αin serum of psoriatic mice(both P<0.05).Tanshinone capsule could also induce the increase of Nrf2,HO-1,and SOD2 in the skin tissue of psoriatic mice(all P<0.05).Conclusion Tanshinone capsule can reduce the IL-17A and TNF-αlevels in serum of psoriasis-like mice and activate the Nrf2 signaling pathway,thus exerting the anti-inflammatory and antioxidant stress effects.
作者
徐霞
周欣
梁景耀
彭丽倩
李仰琪
林春生
万长兰
李振洁
李润祥
叶兴东
Xu Xia;Zhou Xin;Liang Jingyao;Peng Liqian;Li Yangqi;Lin Chunsheng;Wan Changlan;Li Zhenjie;Li Runxiang;Ye Xingdong(Department of Dermatology,Guangzhou Institute of Dermatology Prevention and Treatment,Guangzhou 510095,China)
出处
《国际医药卫生导报》
2022年第14期1925-1930,共6页
International Medicine and Health Guidance News
基金
广东省医学科学技术研究基金项目(A2019180)
广东省中医药局科研项目(20191253)
广州市卫生健康科技项目(20191A010052,20201A010049)。